Wang Jian, Yuan Wei, Yue Chuang, Dai Feng, Gao Shenglin, Mi Yuanyuan, Bai Yu, Zhang Lifeng, Zuo Li, Wu Xingyu, Zhang Wei
Department of Urology, Third Affiliated Hospital of Nantong University (Affiliated Hospital of Jiangnan University), Wuxi, China.
Department of Cardiology, Taizhou People's Hospital, Taizhou, Jiangsu, China.
J Cell Biochem. 2019 Jul;120(7):11955-11964. doi: 10.1002/jcb.28479. Epub 2019 Feb 20.
Association between ribonuclease L (RNASEL) gene 1623A>C polymorphism and prostate cancer (PCa) susceptibility has been assessed in large quantities of studies but with controversial conclusions. We undertook a pooled analysis containing 7397 PCa cases and 6088 control subjects to assess the correlation between RNASEL 1623A>C polymorphism and PCa risk. Moreover, we used enzyme-linked immunosorbent assay to test the serum RNASEL expression among patients enrolled in our centers and in-silico tools were also utilized. The overall results of our analysis indicated a positive relationship between 1623A>C variant and PCa risk (allelic contrast, odds ratio [OR] = 1.07; 95% confidence interval [CI] = 1.02-1.12; P = 0.575; CC vs AA, OR = 1.14; 95% CI = 1.03-1.26; P = 0.217; CC + CA vs AA, OR = 1.10; 95% CI = 1.01-1.19; P = 0.303; and CC vs CA + AA, OR = 1.08; 95% CI = 1.00-1.17; P = 0.298). In ethnicity subgroup analysis, similar results were especially indicated in African descendants. In addition, serum RNASEL levels in PCa cases with CC + CA genotypes were higher than those with AA genotypes. Our present study showed evidence that RNASEL 1623A>C polymorphism is related to PCa risk, especially in African descendants.
